Tenax Therapeutics (TENX) Operating Expenses (2010 - 2026)

Tenax Therapeutics has disclosed Operating Expenses across 16 years of filings, most recently posting $18.8 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 59.29% year-over-year to $18.8 million; the TTM figure through Jun 2026 stood at $68.6 million (up 95.79% YoY), while the FY2025 annual figure was $56.4 million, up 189.24% from the prior year.
• Operating Expenses came in at $18.8 million for Q2 2026 at Tenax Therapeutics, up from $16.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $18.8 million in Q2 2026 to a low of $1.2 million in Q2 2023.
• Average Operating Expenses over 5 years is $7.3 million, with a median of $3.8 million recorded in 2024.
• Year-over-year, Operating Expenses slumped 88.55% in 2022 and jumped 263.84% in 2025.
• Over 5 years, Operating Expenses stood at $2.6 million in 2022, then surged by 30.78% to $3.3 million in 2023, then jumped by 118.35% to $7.3 million in 2024, then soared by 125.48% to $16.4 million in 2025, then advanced by 14.2% to $18.8 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $18.8 million in Q2 2026, $16.6 million in Q1 2026, and $16.4 million in Q4 2025.